News about a potential treatment for achondroplasia, meclizine, being tested by a Japanese team, from the ICCBH 2015 in Salzburg.

Comments by Mark Schoenebaum, Biotech/Pharma analyst since 2000 MD, Johns Hopkins School of Medicine, 2000 BA, Indiana University, 1995 with 6 key tidbits about BMN-111 (vosoritide).

BioMarin announced positive results of a Phase 2 proof-of-concept and dose finding study of BMN 111. now known as vosoritide, a drug in development for achondroplasia.

News on the BMN-111 Phase II clinical trial by BioMarin.

Since the discovery of induced Pluripotent Stem cells, this kind of cell, which can become most types of cells in the organism, have been used in a variety of research programs. Now it's being used in drug discovery for achondroplasia, in this case, to test statins for their capacity of inducing differentiation of these cells into cartilage cells.

There's News on the Phase 2 clinical trial for BMN-111 from BioMarin. The company is enrolling more children into the clinical trial, which is an indication that the data for the Phase 2 is favorable and with reduced side effects.